US-China Biomedical Technology (UCBB) 10-Q2020 Q1 Quarterly report

Filed: 22 Jul 19, 4:45pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abandonment, acute, adoptedASU, affiliate, amortized, analyze, Analyzer, Andrew, Angina, annum, artery, aspect, asset, assist, ASU, average, awaiting, back, Bill, borrowed, borrowing, BSP, cardiac, classification, classified, clinical, collateralized, commencement, comparison, component, configurable, consent, consolidated, CONSTITUTE, consulting, contractual, coronary, creation, deceased, decided, derive, disease, dividend, duration, ECG, electrocardiogram, Elevation, estate, exact, exercisable, exercise, experienced, exporting, facilitate, facility, FASB, fixed, frequency, group, half, hire, History, HyperQ, immaterial, impairment, implicit, imputed, inclusive, income, incremental, innovative, interface, issuable, issuedASU, JV, level, maturity, measure, measured, measurement, method, MI, model, module, monitor, Movassaghi, NSTEMI, OEM, option, optional, Organization, ownership, package, perspective, practical, prepaid, probate, QRS, quantifiable, ramped, range, rate, readily, recognize, recognized, recognizelease, recoverable, reduced, reduction, repayment, rest, revolutionizing, routine, Safa, secondary, segment, separate, share, single, son, staffing, standard, stockholder, sublease, Summary, Targeted, Thetable, Topic, Treasury, treatment, typically, UA, underASU, underlying, unique, Unstable, utilize, variable, venture, VIE, volatility, voted, warrant, Werecognize, yield

Removed: activity, Amanda, area, August, began, Committee, converted, detained, discretion, excluding, grant, Incentive, Liu, maximum, MyComputerKey, newly, Ning, originally, primarily, proceed, promissory, property, resignation, resigned, reversed, risk, Senior, shareholder, split, successfully, threatening, travel, unrelated, Vice

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

UCBB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of US-China Biomedical Technology, Inc., a Nevada corporation, (the “Company”) on Form 10-Q for the period ending May 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Qingxi Huang, Chief Executive Officer of the Company, certify the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: July 22, 2019	By:	/s/ Qingxi Huang
		Qingxi Huang
		Chief (Principal) Executive Officer